Abstract: Methods and devices for microfluidic detection of a biological maker in a biospecimen collected from a subject are disclosed. The microfluidic devices include nanoparticle-based nanosensors comprising supramolecular recognition sequences, protease consensus sequences, post-translationally modifiable sequences, or sterically hindered benzylether bonds for specific interaction with a biological marker. Also disclosed are particular nanosensors for detecting cytokines, and other proteins based upon supramolecular recognition without chemical modification or enzymatic cleavage.
Type:
Grant
Filed:
March 24, 2017
Date of Patent:
April 23, 2024
Assignees:
Kansas State University Research Foundation, Board of Regents of The University of Texas System
Inventors:
Massoud Motamedi, Allan R. Brasier, Stefan H. Bossmann, Christopher T. Culbertson, Deryl Troyer
Abstract: Described herein are novel lipid compositions comprising unsaturated dendrimers and methods of synthesis of unsaturated dendrimers. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Also described herein are pharmaceutical formulations comprising an unsaturated dendrimer, a lipid composition, and a therapeutic agent. Further described in here are methods of mRNA delivery comprising a lipid composition and a therapeutic agent. Further described herein are high-potency dosage forms of a therapeutic formulated with a lipid composition.
Type:
Application
Filed:
December 9, 2021
Publication date:
April 18, 2024
Applicant:
The Board of Regents of The University of Texas System
Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.
Type:
Application
Filed:
June 9, 2023
Publication date:
April 18, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Disclosed herein are electrolytes and electrochemical devices. The electrochemical devices comprise cathodes that include nickel-rich layered lithium transition metal oxides, lithium-rich layered transition-metal oxides, lithium manganese-based spinel oxides, lithium polyanion-based compounds, and combinations thereof. The electrolytes include a lithium imide salt, an aprotic acyclic carbonate solvent, and an additive, wherein the additive comprises a metal salt, an aprotic solvent, or a combination thereof. The electrolyte can be stable at a voltage of 4.3 V or above vs. Li/Li+.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
April 16, 2024
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.
Type:
Grant
Filed:
September 22, 2021
Date of Patent:
April 16, 2024
Assignees:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, GOLGI NEUROSCIENCES, S.R.L.
Inventors:
Paolo Pevarello, William J. Ray, Mary Hamby, Yaima Luzardo Lightfoot, Philip Jones, Russell Thomas, Chiara Liberati, Domenica Torino, Valentina Cusano, Francesco Piscitelli, Ali Munaim Yousif, Silvia Bovolenta
Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Type:
Grant
Filed:
April 25, 2022
Date of Patent:
April 16, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.
Type:
Application
Filed:
August 14, 2023
Publication date:
April 11, 2024
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Jinming GAO, Gang HUANG, Tian ZHAO, Xinpeng MA, Yiguang WANG, Yang LI, Baran D. SUMER
Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
Type:
Application
Filed:
November 13, 2023
Publication date:
April 11, 2024
Applicant:
The Board of Regents of The University of Texas System
Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
Type:
Application
Filed:
November 13, 2023
Publication date:
April 11, 2024
Applicant:
The Board of Regents of The University of Texas System
Abstract: Systems, apparatuses, and methods provide various progressive, bit-level representations of digital data that are useful for a variety of systems and applications within the fields of machine learning, signal and data processing, and data analytics. Systems, apparatus, and methods for such representations incorporate one or more systems for machine learning, predicting, compressing and decompressing data, and are progressive such that the representations embody a sequential organization of information that prioritizes more information over less significant information. Embodiments of the present disclosure include systems for denoising, enhancing, compressing, decompressing, storing, and transmitting digitized media such as text, audio, image, and video. Methods can include partitioning data, modeling partitioned data, predicting partitioned data, transforming partitioned data, analyzing partitioned data, organizing partitioned data, and partially or fully restructuring the original data.
Type:
Application
Filed:
October 13, 2023
Publication date:
April 11, 2024
Applicant:
Board of Regents, The University of Texas System
Inventors:
RICHARD E. S. LISTER METZLER, SOS S. AGAIAN
Abstract: The present disclosure provides ammonium compounds, e.g., compounds according to Formula I as set forth herein, which are useful as antimicrobial agents. Methods for the treatment of bacterial infections and associated conditions, e.g., gastrointestinal conditions, are also described, as well as methods for altering the microbiome of subjects such as humans.
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
April 9, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Bryan Davies, Stanton McHardy, Ashley Cunningham, Hua-Yu Wang
Abstract: Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer.
Type:
Grant
Filed:
October 5, 2023
Date of Patent:
April 9, 2024
Assignees:
Moleculin Biotech, Inc., Board of Regents, The University of Texas System
Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to a new class of small-molecules having a pyrazino-pyrimidine-dione (or related) structure which function as modulators (activators, inhibitors) of protease activated receptor type 2 (PAR2), and their use as therapeutics for the treatment of conditions involving PAR2 activity (e.g., asthma, chronic pain, cancer and/or vascular disorders).
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
April 9, 2024
Assignees:
Arizona Board of Regents on Behalf of the University of Arizona, Board of Regents, The University of Texas System
Inventors:
Scott A. Boitano, Josef Vagner, Theodore J. Price, Greg Dussor
Abstract: Aspects of the present disclosure are directed to methods for treating a subject having cancer. Certain aspects relate to treating a subject for lung cancer by administering poziotinib to a subject determined, from analysis of tumor DNA from the subject, to have an EGFR mutation of a particular classification. Further aspects relate to methods for treating a subject for lung cancer by detecting an EGFR mutation of a particular classification in tumor DNA from the subject and administering an effective amount of poziotinib to the subject. Also disclosed are methods for stratifying and prognosing subjects based on EGFR mutation classification.
Type:
Application
Filed:
January 28, 2022
Publication date:
April 4, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Jacqulyne P. ROBICHAUX, John V. HEYMACH
Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.
Type:
Application
Filed:
October 12, 2023
Publication date:
April 4, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Maria A. CROYLE, Jin Huk CHOI, Stephen Clay SCHAFER
Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.
Type:
Grant
Filed:
July 28, 2021
Date of Patent:
April 2, 2024
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Embodiments may provide techniques that protect voice-controllable devices and systems such that the microphone can be shielded from attacking modulated laser beams. Embodiments may provide a physical device that may include two or more layers of integrated material that sits on top of the microphones of the voice-controllable devices and/or systems. The device may act as a physical barrier against the injected malicious laser beams while allowing sound waves reach the microphone for normal operation. For example, in an embodiment, an apparatus may comprise a first layer including at least one opening and a second layer including at least one opening, wherein the at least one opening in the first layer and the at least one opening in the second layer are arranged so as to block the passage of light, but to allow the passage of sound.
Type:
Grant
Filed:
March 11, 2021
Date of Patent:
April 2, 2024
Assignee:
Board of Regents, The University of Texas System
Abstract: Methods and compositions used to identify and characterize novel rhodopsin domains, which are kalium (potassium)-conducting channelrhodopsins. The rhodopsin domain of these kalium (potassium)-conducting channelrhodopsins have been cloned, optimized and expressed in mammalian systems and thus may be used in, among others, optogenetic applications and as therapeutic agents for electrically active cell mediated disorders.
Type:
Application
Filed:
September 12, 2023
Publication date:
March 28, 2024
Applicants:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, BAYLOR COLLEGE OF MEDICINE
Inventors:
John Lee SPUDICH, Elena G. GOVORUNOVA, Oleg A. SINESHCHEKOV, Mingshan XUE
Abstract: Aspects of the present disclosure are directed to methods for treating a subject having cancer. Certain aspects relate to treatment with an anthracene derivative after treatment with one or more pyrimidine analog antimetabolites. Further aspects relate to methods for improving the efficacy of one or more pyrimidine analog antimetabolites by administering to a subject a therapeutically effective amount of an anthracene derivative after administration of the one or more pyrimidine analog antimetabolites.
Type:
Application
Filed:
January 19, 2022
Publication date:
March 28, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM